News stories about American Renal Associates Holdings (NYSE:ARA) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. American Renal Associates Holdings earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.9777964895179 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

American Renal Associates Holdings (NYSE ARA) traded down 0.39% during midday trading on Friday, reaching $15.42. 167,679 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $14.88 and a 200-day moving average of $14.88. The stock’s market cap is $482.41 million. American Renal Associates Holdings has a 12 month low of $14.00 and a 12 month high of $24.94.

American Renal Associates Holdings (NYSE:ARA) last announced its earnings results on Tuesday, August 8th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.04. The business had revenue of $185.99 million for the quarter, compared to the consensus estimate of $188.23 million. American Renal Associates Holdings had a negative net margin of 1.54% and a positive return on equity of 18.25%. American Renal Associates Holdings’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities research analysts predict that American Renal Associates Holdings will post $0.54 earnings per share for the current year.

Separately, Zacks Investment Research cut shares of American Renal Associates Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $22.33.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/06/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-american-renal-associates-holdings-ara-share-price.html.

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Insider Buying and Selling by Quarter for American Renal Associates Holdings (NYSE:ARA)

Receive News & Stock Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related stocks with our FREE daily email newsletter.